Glycopyrronium
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Glycopyrronium |
| DrugBank ID | DB00986 |
| Brand Names (EU) | Glycopyrronium |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.84% |
Approved Indication (EMA)
Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | irritable bowel syndrome | 98.84% | DL |
| 2 | cauda equina syndrome | 98.51% | DL |
| 3 | obsolete neurogenic bladder (disease) | 97.73% | DL |
| 4 | neurocirculatory asthenia | 96.91% | DL |
| 5 | migraine disorder | 96.08% | DL |
| 6 | migraine with brainstem aura | 95.68% | DL |
| 7 | open-angle glaucoma | 95.61% | DL |
| 8 | autonomic nervous system disease | 95.55% | DL |
| 9 | primary hereditary glaucoma | 95.30% | DL |
| 10 | dysthymic disorder | 93.68% | DL |
| 11 | common cold | 93.27% | DL |
| 12 | dysautonomia | 92.51% | DL |
| 13 | headache disorder | 90.90% | DL |
| 14 | familial mitral valve prolapse | 90.49% | DL |
| 15 | mitral valve prolapse (disease) | 90.45% | DL |
| 16 | insomnia (disease) | 89.67% | DL |
| 17 | MVP1 | 89.48% | DL |
| 18 | multiple system atrophy | 89.27% | DL |
| 19 | trigeminal autonomic cephalalgia | 89.19% | DL |
| 20 | atrophoderma vermiculata | 88.78% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.